Dougherty, BA;
Lai, Z;
Hodgson, DR;
Orr, MCM;
Hawryluk, M;
Sun, J;
Yelensky, R;
... Barrett, JC; + view all
(2017)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
, 8
(27)
pp. 43653-43661.
10.18632/oncotarget.17613.
Preview |
Text
Ledermann_17613-257535-8-PB.pdf - Published Version Download (944kB) | Preview |
Preview |
Text (Supplementary figures)
Dougherty_Biological_clinical_evidence_somatic_mutations_Suppl_1.pdf Download (571kB) | Preview |
Preview |
Text (Supplementary tables)
Dougherty_Biological_clinical_evidence_somatic_mutations_Suppl2.pdf Download (361kB) | Preview |
Abstract
To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 patients with platinum-sensitive high-grade serous ovarian cancer. BRCA1/2 loss-of-function mutations were found in 55% (114/209) of tumors, were mutually exclusive, and demonstrated high concordance with Sanger-sequenced germline mutations in matched blood samples, confirming the accuracy (97%) of tumor BRCA1/2 NGS testing. Additionally, NGS identified somatic mutations absent from germline testing in 10% (20/209) of the patients. Somatic mutations had >80% biallelic inactivation frequency and were predominantly clonal, suggesting that BRCA1/2 loss occurs early in the development of these cancers. Clinical outcomes between placebo- and olaparib-treated patients with somatic BRCA1/2 mutations were similar to those with germline BRCA1/2 mutations, indicating that patients with somatic BRCA1/2 mutations benefit from treatment with olaparib.
| Type: | Article |
|---|---|
| Title: | Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.18632/oncotarget.17613 |
| Publisher version: | http://doi.org/10.18632/oncotarget.17613 |
| Language: | English |
| Additional information: | Copyright © Dougherty et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Keywords: | BRCA, germline, olaparib, ovarian, somatic |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1559038 |
Archive Staff Only
 |
View Item |
